Antibody–drug conjugates: Pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned.
Abstract
Antibody–drug conjugates are an emerging class of biopharmaceuticals changing the landscape of targeted chemotherapy. These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. Several antibody–drug conjugates have received approval for the treatment of various types of cancer including gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), trastuzumab...
Paper Details
Title
Antibody–drug conjugates: Pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned.
Published Date
Jun 1, 2018
Journal
Volume
57
Issue
6
Pages
687 - 703
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History